Management of Cardiovascular Health in People with Severe Mental Disorders

Curr Cardiol Rep. 2021 Jan 6;23(2):7. doi: 10.1007/s11886-020-01436-5.

Abstract

Purpose of review: To review evidence regarding the association between bipolar disorder and schizophrenia, henceforth referred to as severe mental disorders (SMD), and cardiovascular morbidity and mortality, its mechanisms, and the interventions to reduce this burden.

Recent findings: Much of the loss in life expectancy in people with SMD remains driven by cardiovascular mortality. Antipsychotics and mood stabilizers are associated with negative cardio-metabolic outcomes, but large inter-individual differences are observed, and not treating SMD might be associated with even greater cardiovascular mortality. Classical modifiable cardiovascular risk factors remained inadequately screened and, once identified, too seldom treated in people with SMD. After a myocardial infarction, aggressive tertiary prevention may be as effective in people with SMD as in the general population but is less prescribed. Reduced healthcare quality and increased prevalence of cardiovascular risk factors may not fully explain the excess cardiovascular mortality associated with SMDs, which themselves should be considered risk factors in risk calculators. Hazardous health behaviors, the cardio-metabolic adverse effects of medications, and a reduced access to quality healthcare remain priority targets for intervention.

Keywords: Bipolar disorder; Cardiovascular disease; Mortality; Prevention; Schizophrenia.

Publication types

  • Review

MeSH terms

  • Anticonvulsants / therapeutic use
  • Antipsychotic Agents* / adverse effects
  • Bipolar Disorder* / complications
  • Bipolar Disorder* / drug therapy
  • Humans
  • Risk Factors

Substances

  • Anticonvulsants
  • Antipsychotic Agents